TOLREMO therapeutics AG
tolremo.com
Actively hiring
Biotechnology
As featured in
Follow
Overview
News
Salaries
Products
People
Growth
Offices
Financials
News
TOLREMO therapeutics Completes Phase I Study of TT125-80 and Presents Final Clinical Data at World Conference on Lung Cancer 2026
Final Phase 1 data provide clinical validation of CBP/p300 as a novel therapeutic target for overcoming transcriptional resistance in NSCLCTT125-8...
Read more
Report
Tolremo therapeutics completes first in human dose escalation for TT125-802 and presents solid tumour monotherapy results at ESMO 2025
Tolremo therapeutics completes first in human dose escalation for TT125-802 and presents solid tumour monotherapy results at ESMO 2025
Read more
Report
TOLREMO therapeutics Completes First In Human Dose Escalation for TT125-802 and Presents Solid Tumor Monotherapy Results at ESMO 2025
Monotherapy shows deep and durable responses in NSCLC and a best-in-class safety profile without thrombocytopeniaCompletion of monotherapy dose escalation part of the study will be followed by the start of combination studies in EGFRmut, KRAS-G12Cmut and
Read more
Report
Tolremo therapeutics receives two US FDA fast track designations for TT125-802 in pretreated, advanced or metastatic NSCLC with either an EGFR or a KRAS-G12C mutation
Tolremo therapeutics receives two US FDA fast track designations for TT125-802 in pretreated, advanced or metastatic NSCLC with either an EGFR or a KRAS-G12C mutation
Read more
Report
TOLREMO therapeutics Receives Two FDA Fast Track Designations for TT125-802 in Pretreated, Advanced or Metastatic NSCLC With Either an EGFR or a KRAS-G12C Mutation
TT125-802 is a small molecule CBP/p300 bromodomain inhibitor that shows clinical activity as single agent in solid tumors, including advanced EGFR-mutated and KRAS-G12C-mutated non-small cell lung cancer (NSCLC)1 in 5 cancer-related deaths in the US are d
Read more
Report
TOLREMO therapeutics Receives Two FDA Fast Track Designations for TT125-802 in Pretreated, Advanced or Metastatic NSCLC With Either an EGFR or a KRAS-G12C Mutation
TT125-802 is a small molecule CBP/p300 bromodomain inhibitor that shows clinical activity as single agent in solid tumors, including advanced EGFR-mutated and KRAS-G12C-mutated non-small cell lung cancer (NSCLC) 1 in 5 cancer-related deaths in the US are
Read more
Report
TOLREMO therapeutics Announces TT125-802 is the First CBP/p300 Bromodomain Inhibitor to Show Clinical Activity in Solid Tumors
media645257
Read more
Report
TOLREMO therapeutics AG: TOLREMO Treats First Patient in Phase I Trial with TT125-802, a Novel Therapeutic Agent to Overcome Transcriptional Cancer Drug Resistance
TOLREMO therapeutics AG (TOLREMO) today announced that the first patient has been dosed in its first-in-human clinical trial evaluating the safety and tolerability, pharmacokinetics, and pharmacodynamics
Read more
Report
Offices
Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Basel
Switzerland
Registered seat
Financials
Total raised
$39M
Latest round
Series A
Funding rounds
1
Funding rounds
| Round | Announced | Amount | |
|---|---|---|---|
| Series A | 2023 | $39M | Details |